Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological diseases. Its mission focuses on addressing the unmet needs of patients with conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Biogen's strategy emphasizes cutting-edge research, collaboration with academic institutions, and leveraging advanced technologies to enhance drug development. The company operates through a robust pipeline of therapies and a commitment to patient-centric solutions, aiming to improve the quality of life for individuals affected by debilitating neurological disorders.

BIOGEN INC

Biogen Inc. is making a significant move in the treatment of Dravet syndrome, a severe genetic epilepsy, by partnering with Stoke Therapeutics to develop and market zorevunersen. As per the terms of the deal, Biogen will pay an upfront fee of $165 million and may pay up to an additional...

Biogen Invests $165 Million in Partnership with Stoke Therapeutics to Develop zorevunersen for Dravet Syndrome Treatment

Biogen's $165 million investment in zorevunersen, a promising treatment for Dravet syndrome, marks a pivotal shift towards rare disease solutions. As they partner with Stoke Therapeutics, can this innovative approach redefine patient outcomes in genetic epilepsy?